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SUMMARY Spitzoid melanomas (SM) and atypical Spitz tumors (AST) are rare pediatric 
neoplasms. We performed a retrospective, single-institution review and report our 
institutional experience. We identified 10 patients (median age: 12.5 years). A sentinel node 
biopsy (SNB) was performed in 8/10 (80%) patients, and interestingly 7/8 (87.5%) were found 
to be positive for malignant cells. A complete regional lymphadenectomy was performed 
in all SNB-positive patients, but only 2/8 (25%) were found to have additional lymph node 
spread. Adjuvant therapy was administered in 5/8 SLNB-positive and 2/2 (100%) regional 
LN-positive cases. All patients had excellent long-term outcomes (100% survival). This report 
highlights the excellent outcomes associated with SNB + pediatric SM and AST.
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Spitzoid melanoma (SM) and atypical Spitz tumors (AST) are rare neoplasms that affect children. 
SM and AST often pose a diagnostic challenge, as these lesions are often hard to distinguish from 
adult type malignant melanoma (MM) based on pathologic criteria [1,2]. The optimal management of 
SM/AST remains controversial [3]. Management usually consists of surgical removal of large, rapidly 
changing lesions with atypical dermoscopic or histological features [4,5]. Complete lymphadenectomy 
is usually performed in patients with sentinel lymph node positivity [5–8].
This report summarizes our institutional experience in treating these rare pediatric tumors.
Methods
We retrospectively collected clinical data from the melanoma database in patients ≤21 years of 
age diagnosed with SM/AST from 1980–2014, at Riley Hospital for Children, Indianapolis, after 
approval by our Institutional review Board. Every year, approximately two to four pediatric patients 
with newly diagnosed melanoma are diagnosed and treated at Riley Hospital.
Practice points
 ●  Atypical Spitz tumors (AST) and Spitzoid melanomas (SM) are biologically distinct from adult type melanomas (MM).
 ●  AST and SM are usually treated as per current MM management guidelines.
 ●  Existing data suggest that adjuvant therapy may not be necessary in fully resected nonmetastatic sentinel lymph 
node-positive (SLB+) SM/AST and that these patients could be observed as they are unlikely to recur.
 ●  A great degree of variability exists in the management of these tumors amongst pediatric oncologists.
 ●  Further molecular studies are needed to understand the unique biological behavior of AST/SM. These studies 
may ultimately lead to important insights into transformation of benign nevi into melanomas and identify new 
therapeutic targets in advanced melanoma.
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The tumors were classified as AST or SM if 
they displayed all or some of the following fea-
tures: asymmetry, epidermal effacement, high 
cellular density, cytological atypia, high nuclear/
cytoplasmic ration, mitotic rate >2/mm2 (AST 
and SM) and a high degree of pleomorphism 
(SM) [9,10]. In all patients, a second opinion from 
an external expert pathologist was obtained, 
to confirm the diagnosis. However, some of 
the cases were diagnosed and managed in the 
1980s and 1990s, and the pathological criteria at 
that time might have been less defined than the 
current criteria. Thus a limitation of this study 
is observer bias.
Results
Ten cases of SM/AST were diagnosed and man-
aged at our institution from 1980–2014. The his-
topathological features and patient demograph-
ics, treatment and outcomes are summarized in 
Tables 1 & 2, respectively.
The median age of the ten patients was 
12.5 years. The median follow-up was for 
34 months. All patients were alive, with no 
local or distant disease recurrence. Six out of 
ten patients had a complete and wide excision of 
the primary lesion with negative margins. Four 
patients (patient # 2, 3, 5 and 6) underwent a 
re-excision with negative margins. A SLB was 
performed for all stage III lesion (8/10 = 80%) 
and was found to positive (SLB+) for atypical 
malignant cells in 7/8 (87.5%, 6/8 of these 
had isolated tumor cells and 1/8 [patient #6] 
had extensive involvement) samples. All SLB+ 
patients underwent a regional lymph node dis-
section (LND) but only 2/8 (25%) of the dis-
sected lymph nodes were positive (LND+) for 
malignant cells.
Two patients (# 2 and 5), who were SLB+/
LND-, were observed and received no further 
therapy. Three patients (patient numbers 3, 4 
and 8, SLB+, LND-) received adjuvant immu-
notherapy (interferon [IFN]) (Table 2). Both 
patients with regional nodal disease (patient 
numbers 6 and 10) received IFN and local radio-
therapy (RT) or IFN only respectively (Table 2). 
Patient numbers 1 and 7 did not undergo a SLB 
and were presumed to be stage II.
Abnormal and varied cytogenetics were docu-
mented in four patients (patient # 2, 3, 5 and 
7). Melanoma specific FISH probes, BRAF and 
RAS mutations were not tested in these patients. 
Interestingly, the two SLB+ patients, who were 
observed, were found to have atypical cytoge-
netic findings of 6q-, total loss of chromosome 
9 and 10, and 1q-, 2p-, loss of chromosome 
9 and 19, respectively, remained relapse free 
17 months and 50 months postresection.
Discussion
SM/AST are rare pediatric tumors that are a 
distinct clinicopathologic entity, first described 
by Spitz in 1948. Consistent with our results, 
a higher incidence of sentinel node positivity 
(SLB+) has been reported in SM/AST com-
pared with malignant melanoma [6–7,11]. The 
higher incidence of SLB+ is usually not asso-
ciated with either extensive nodal involvement 
or distant metastasis, especially in prepubes-
cent children (only 25% in our case series) 
and importantly doesn’t usually translate into 
inferior outcomes [7,12–14].
The increased propensity to metastasize to 
local lymph nodes but not distant sites could be 
explained by a vigorous immune reaction, bet-
ter microfiltration, natural involution of lymph 
Table 1. Histopathologic features.
Patient  Histology Breslow thickness Clark 
level
Ulcer V/L 
invasion
Mitosis/
mm2 
Margins Associated 
nevus
Cytogenetics
1 SM NA NA NA NA NA Negative No NA
2 SM Intermediate (1–3.99 mm) IV No No 3 Positive No 6q-, 9-, 10-
3 SM Intermediate IV No NA 12 Positive No 1q-, 2p-, 2q-, 9- (total loss), 19-
4 SM Intermediate NA NA NA NA Negative Yes 3q-, 6p-
5 SM Intermediate NA No NA NA Positive No 2p-, 18-, 16q-, 12q-
6 SM Intermediate III No No NA Negative Yes NA
7 SM Higher risk (>4 mm) IV Yes No NA Negative NA 11p+, 15+, 18+, 22+, 3q-, 13q-
8 AST Intermediate IV No NA NA Negative Yes NA
9 AST NA NA No NA NA NA Yes NA
10 AST Higher risk NA No NA NA NA Yes NA
AST: Atypical Spitz tumors; SM: Spitzoid melanoma; NA: Information not available.
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nodes in the pediatric population [15]. One could 
also hypothesize that the malignant cells that 
are identified in the lymph nodes are nodal 
melanophages that have been over interpreted 
as aggressive melanoma cells [16].
Whether or not SM/AST represent a contin-
uum between benign nevi and aggressive adult 
type malignant melanoma remains a mystery. 
Majority of malignant melanomas demonstrate 
chromosomal aberrations and gene amplifica-
tions [17,18], and loss of replicative senescence 
by telomerase overexpression [19] and angio-
tropism [20]. While the majority of conventional 
pediatric melanomas demonstrate a bigger array 
of chromosomal copy number aberrations, they 
may also demonstrate 6p25, 8q24 and 11q13 
gains, deletions of 6q23 and 9p21, like their 
Spitzoid counterparts [21–25].
Benign Nevi such as blue or congenital nevi 
usually do not exhibit similar cytogenetic abnor-
malities or telomerase overexpression but may 
exhibit angiotropism [26–28].
Using comparative genomic hybridization 
(CGH) and FISH, gains in 6p25 or 11q13 and 
homozygous deletions in 9p21 have been iden-
tified in SM/AST and were found to be asso-
ciated with a more aggressive clinical behavior 
and higher propensity towards metastatic spread 
beyond the sentinel lymph node [22,29].
Based on this observations, one could specu-
late that unique chromosomal aberrations and 
dysregulation of the telomere checkpoint may 
play a role in determining the phenotype of a 
SM/AST [24–25,30–32].
SM also have a unique spectral signature 
further suggesting that these neoplasms are 
biologically unique and differ in pathogenesis 
from MM, especially in the prepubertal pediat-
ric age group [18,33]. A small subset of Spitz nevi 
demonstrate an isolated gain of chromosome 11p 
and HRAS mutations [32,34], a finding not seen 
in adult type melanoma. HRAS mutations seem 
to confer a benign clinical behavior. Unlike con-
ventional melanomas, NRAS mutations are rare 
in Spitzoid lesions [21,35–36]. More recent studies 
have demonstrated the presence of additional 
kinase fusions (ROS1, NTRK1, ALK and RET 
oncogenes) in adult Spitzoid neoplasms [30], but 
little is known of the precise role of these onco-
genes in the transformation of Spitz nevi into 
AST and SM.
Activating mutations of BRAF kinase are 
common in MM [37]. However, BRAF mutations 
have also been found in benign nevi, suggesting 
that BRAF mutation is an early mutagenic event 
that by itself may not confer malignant poten-
tial [35,36]. The heterogeneity of BRAF mutations 
while documented in adult type melanoma and 
other tumor types, have not been elucidated 
in pediatric AST or SMs but warrants further 
investigation [2,21]. Like their adult counterparts, 
the heterogeneity of BRAF mutations, may 
ultimately dictate clinical response to BRAF 
inhibitors in this patient population, and may 
ultimately provide the foundation for the use of 
kinase inhibitors for the treatment of refractory 
SM and ASTs [2,21].
Another biological feature of aggressive MM 
is the ability to evade effective immune response 
possibly by inhibiting T-cell activation [38–40]. 
The PD-1 receptor has been shown to attenuate 
activated T cells to mount an immune response 
Table 2. Patient demographics and clinical follow-up.
Patient Age 
(years)
Sex Site Wide excision Sentinel 
LN
Regional 
LND
Stage Adjuvant therapy Status Follow-
up 
(RFS) 
1 14 Male Extremity Yes No No II No Alive 24
2 6 Female Extremity Yes† Yes(+) Yes (-) IIIA No Alive 17
3 16 Female Extremity Yes† Yes (+) Yes (-) IIIIA IFN × 2 yrs Alive 27
4 10 Male Extremity Yes Yes (+) Yes (-) IIIA IFN × 1 year Alive 34
5 2 Female Head/neck Yes† Yes (+) Yes (-) IIIC No Alive 50
6 13 Male Head/neck Yes† Yes (+) Yes (+)‡ IIIC IFN × 1 year, Local RT Alive 34
7 4 Female Head/neck Yes No No IIC No Alive 84
8 14 Male Head/neck Yes Yes (+) Yes (-) III IFN × 48 weeks Alive 12
9 15 Male Head/neck Yes Yes (-) Yes (-) III No Alive 84
10 12 Male Head/neck Yes Yes (+) Yes (+) III IFN Alive 60
†Patient 2, 3, 5 and 6 underwent a re-excision after partial resection.
‡Patient 6 had multiple regional LN that were positive and had extra capsular local spread.
LN: Lymph node; LND: Lymph node dissection; RFS: Relapse-free survival; RT: Radiotherapy.
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towards melanoma cells [41–43]. Melanoma cells 
produce the ligand (PD-L1) which binds PD-1 
on the T-cell surface. Recent trials have demon-
strated that Ipilimumab, a monoclonal antibody 
to CTLA-4 receptor and PD-1 is efficacious in 
advanced melanoma [43].
One could speculate that one of the reasons, 
majority of ASTs and SMs may not be able to 
evade host immune response and tend to be lim-
ited to local spread, is that they do note attenu-
ate activated T cells via the PD-1 pathway. It 
is plausible that the ASTs or SMs that are fatal 
and metastasize may have effectively evaded host 
response in a similar manner to MM.
Conclusion
A great degree of variability still exists in the 
management of AST and SM among pediat-
ric oncologists especially regarding the use of 
adjuvant therapy in these patients.
In the past, metastatic or aggressive AST or 
SM have been treated as per current MM man-
agement guidelines. However, as our case series 
demonstrates, clinicians should elect to observe 
fully resected nonmetastatic SLB+ SM/AST, 
based on the notion that these are biologically 
a different entity than adult type malignant 
melanoma. While postpubescent state, presence 
of homozygous 9p21 deletion or a high num-
ber of chromosomal aberrations may confer a 
higher risk of advanced local-regional disease, it 
does not necessarily translate into inferior out-
comes [13,44]. Our experience further supports 
the notion that the aggressive clinical approach 
used in adult melanoma may not be applicable to 
sentinel node-positive SM/AST, as the relapse or 
recurrence rate is low with or without adjuvant 
therapy.
Future perspective
AST and SM are clinically and biologically dif-
ferent from MM. Based on our observations 
and emerging clinical data these rare pediatric 
neoplasms may have been overtreated in the 
past, especially if the treating physician fol-
lowed current MM management guidelines. The 
majority of these lesions can simply be excised 
or re-excised, followed by careful physical, 
radiological or echotomographic monitoring of 
the regional nodes.
Little is known about what determines the 
unique clinical behavior of pediatric AST and 
SMs, and why these tumors are associated with 
better outcome even if they metastasize locally. 
Further molecular studies are needed to under-
stand the unique biological behavior of these 
rare pediatric tumors. These studies may ulti-
mately lead to important insights into trans-
formation of benign nevi into melanomas and 
identify new therapeutic targets in advanced 
melanoma.
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